Developing an artificial artery to replace harvested veins in CABG surgery, reducing pain, scarring, and recovery time.
Cardiovascular disease is the #1 cause of death worldwide, with nearly 1 million CABG surgeries performed each year.
Vein harvesting increases pain, risk of infection, longer recovery, and has high failure rates.
A regenerative, biocompatible, and thrombo-resistant artificial artery designed to be flexible, strong, and long-lasting.
Animal studies surpassed the 90-day FDA requirement and continued over 180 days; human trials are being prepared.
An estimated $8–10 billion market with a need for 2–3 million grafts per year worldwide.
Eliminates vein harvesting, reduces failure rates, shortens surgery and recovery times, and expands eligibility to more patients.
US hospitals and worldwide distribution with a partnership with Mayo Clinic.
$5.80 per share, $116 minimum investment, $40M target raise through Regulation A offering.
Includes experts in cardiovascular research, biomedical engineering, and manufacturing with decades of medical device experience.
Renowned cardiac surgeons, biomedical engineers, and medtech business leaders advising product and market strategy.
SEC-qualified offering; investors should read the offering circular before investing.